Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)

Gyre Therapeutics has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $9.6 million for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 15.66% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, up 15.66% year-over-year, with the annual reading at $9.6 million for FY2025, 15.66% up from the prior year.
  • Non-Current Deferred Tax Liability was $9.6 million for Q4 2025 at Gyre Therapeutics, up from $8.3 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $9.6 million in Q4 2025 and troughed at $2.5 million in Q4 2023.
  • The 3-year median for Non-Current Deferred Tax Liability is $8.3 million (2024), against an average of $6.8 million.
  • Year-over-year, Non-Current Deferred Tax Liability surged 232.0% in 2024 and then rose 15.66% in 2025.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $2.5 million in 2023, then surged by 232.0% to $8.3 million in 2024, then increased by 15.66% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non-Current Deferred Tax Liability are $9.6 million (Q4 2025), $8.3 million (Q4 2024), and $2.5 million (Q4 2023).